A thyroid tumor-specific antigen formed by the fusion of two self proteins

Journal of Immunology

Volumn 170, Issue 2, 2003, Pages 861-869

  Powell Jr , Daniel J ^a   Eisenlohr, Laurence C ^a   Rothstein, Jay L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; PROTEIN; PROTEIN PATCHED; PROTEIN RET; PROTEIN RP3; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSION GENE; HASHIMOTO DISEASE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; THYROID CELL; THYROID DISEASE; THYROID TUMOR; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0037438481     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.2.861     Document Type: Article

References (38)

1. Becker, K. L. 1995. Principles and Practices of Endocrinology and Metabolism. J. B. Lippincott Company, Philadelphia, PA.
2. Rosenberg, S. A., and D. E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81.
3. Bongarzone, I., M. A. Pierotti, N. Monzini, P. Mondellini, G. Manenti, R. Donghi, S. Pilotti, M. Grieco, M. Santoro, A. Fusco, et al. 1989. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4:1457.
4. -/- mice. Oncogene 20:3235.
5. Ries, L. A. G., M. P. Eisner, C. L. Kosary, B. F. Hankey, B. A. Miller, L. Clegg, and B. K. Edwards, eds. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute. Bethesda, MD.
6. Rabes, H. M., E. P. Demidchik, J. D. Sidorow, E. Lengfelder, C. Beimfohr, D. Hoelzel, and S. Klugbauer. 2000. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 6:1093.
7. Kroll, T. G., P. Sarraf, L. Pecciarini, C. J. Chen, E. Mueller, B. M. Spiegelman, and J. A. Fletcher. 2000. PAX8-PPARγl fusion in oncogene human thyroid carcinoma. Science 289:1357.
8. Santoro, M., N. A. Dathan, M. T. Berlingieri, I. Bongarzone, C. Paulin, M. Grieco, M. A. Pierotti, G. Vecchio, and A. Fusco. 1994. Molecular characterization of RET/PTC3: a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509.
9. Gao, T., K. Brantley, E. Bolu, and M. J. McPhaul. 1999. RFG (ARA70. ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol. Endocrinol. 13:1645.
10. Wirtschafter, A., R. Schmidt, D. Rosen, N. Kundu, M. Santoro, A. Fusco, H. Multhaupt, J. P. Atkins, M. R. Rosen, W. M. Keane, and J. L. Rothstein. 1997. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107:95.
11. Sheils, O. M., J. O'Eary, V. Uhlmann, K. Lattich, and E. C. Sweeney. 2000. ret/PTC-1 activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 8:185.
12. Mizuno, T., S. Kyoizumi, T. Suzuki, K. S. Iwamoto, and T. Seyama, 1997. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15:1455.
13. Santoro, M., M. Papotti, G. Chiappetta, G. Garcia-Rostan, M. Volante, C. Johnson, R. L. Camp, F. Pentimalli, C. Monaco, A. Herrero, et al. 2002. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 87:370.
14. Tallini, G., M. Santoro, M. Helie, F. Carlomagno, G. Salvatore, G. Chiappetta, M. L. Carcangiu, and A. Fusco. 1998. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 4:287.
15. Vogelstein, B., E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert, Y. Nakamura, R. White, A. M. Smits, and J. L. Bos. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319:525.
16. Chen, W., D. J. Peace, D. K. Rovira, S. G. You, and M. A. Cheever. 1992. T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA 89:1468.
17. Bocchia, M., T. Korontsvit, Q. Xu, S. Mackinnon, S. Y. Yang, A. Sette, and D. A. Scheinberg. 1996. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587.
18. Ten Bosch, G. J., A. C. Toornvliet, T. Friede, C. J. Melief, and O. C. Leeksma. 1995. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9:1344.
19. Pawelec, G., H. Max, T. Halder, O. Bruserud, A. Merl, P. da Silva, and H. Kalbacher. 1996. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118.
20. Matsubayashi, S., K. Kawai, Y. Matsumoto, T. Mukuta, T. Morita, K. Hirai, F. Matsuzuka, K. Kakudoh, K. Kuma, and H. Tamai. 1995. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J. Clin. Endocrinol. Metab. 80:3421.
21. Dailey, M. E., S. Lindsay, and R. Skahen. 1955. Relation of thyroid neoplasms to Hashimoto disease of the thyroid. Arch. Surg. 70:291.
22. Segal, K., M. Ben-Bassat, A. Avraham, G. Har-El, and J. Sidi. 1985. Hashimoto's thyroiditis and carcinoma of the thyroid gland. Int. Surg. 70:205.
23. Powell, D. J., Jr., J. Russell, K. Nibu, G. Li, E. Rhee, M. Liao, M. Goldstein, W. M. Keane, M. Santoro, A. Fusco, and J. L. Rothstein. 1998. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58:5523.
24. Eisenlohr, L. C., J. W. Yewdell, and J. R. Bennink. 1992. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J. Exp. Med. 175:481.
25. Jhiang, S. M., J. E. Sagartz, Q. Tong, J. Parker-Thornburg, C. C. Capen, J. Y. Cho, S. Xing, and C. Ledent. 1996. Targeted expression of the ret/PTCI oncogene induces papillary thyroid carcinomas. Endocrinology 137:375.
26. Santoro, M., G. Chiappetta, A. Cerrato, D. Salvatore, L. Zhang, G. Manzo, A. Picone, G. Portella, G. Santelli, G. Vecchio, and A. Fusco. 1996. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTCI oncogene in transgenic mice. Oncogene 12:1821.
27. Akkaraju, S., W. Y. Ho, D. Leong, K. Canaan, M. M. Davis, and C. C. Goodnow. 1997. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immmunity 7:255.
28. Gerard, C. M., N. Baudson, K. Kraemer, C. Ledent, D. Pardoll, and C. Bruck. 2001. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin. Cancer Res. 7:838s.
29. Mukherjee, P., A. Dani, S, Bhatia, N. Singh, A. Y. Rudensky, A. George, V. Bal, S. Mayor, and S. Rath. 2001. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis. J. Immunol. 167:2632.
30. Watts, C., A. Antoniou, B. Manoury, E. W. Hewitt, L. M. McKay, L. Grayson, N. F. Fairweather, P. Emsley, N. Isaacs, and P. D. Simitsek. 1998. Modulation by epitope-specific antibodies of class II MHC-restricted presentation of the tetanus toxin antigen. Immunol. Rev. 164:11.
31. Metaye, T., J. L. Kraimps, J. M. Goujon, B. Fernandez, N. Quellard, P. Ingrand, J. Barbier, and F. Begon. 1997. Expression, localization, and thyrotropin regulation of cathepsin D in human thyroid tissues. J. Clin. Endocrinol. Metab. 82:3383.
32. Shuja, S., and M. J. Murnane. 1996. Marked increases in cathepsin B and L activities distinguish papillary carcinoma of the thyroid from normal thyroid or thyroid with non-neoplastic disease. Int. J. Cancer 66:420.
33. Isakov, N., and S. Segal. 1983. Immunogenicity of the mutated H-2Kbm1 antigen(s): test of thyroid graft rejection between B6.C-H-2bm1 and C57BL/6 mice following reciprocal immunization with normal versus malignant cells. Immunobiology 165:485.
34. Frazer, I. H., D. M. Leippe, L. A. Dunn, A. Liem, R. W. Tindle, G. J. Fernando, W. C. Phelps, and P. F. Lambert. 1995. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55:2635.
35. Doan, T., K. A. Herd, P. F. Lambert, G. J. Fernando, M. D. Street, and R. W. Tindle. 2000. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. 60:2810.
36. Frazer, I. H., R. De Kluyver, G. R. Leggatt, H. Y. Guo, L. Dunn, O. White, C. Harris, A. Liem, and P. Lambert. 2001. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 167:6180.
37. Koeppen, H. K., S. Singh, H. J. Stauss, B. H. Park, D. A. Rowley, and H. Schreiber. 1993. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation 55:1349.
38. Fusco, A., G. Chiappetta, P. Hui, G. Garcia-Rostan, L. Golden, B. K. Kinder, D. A. Dillon, A. Giuliano, A. M. Cirafici, M. Santoro, et al. 2002. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 160:2157.